European and other developed countries that have imposed drug-price controls are free-riding on the research and development (R&D) investment of the U.S. and a handful of other countries, a new study has found.
Stephen Ezell, vice president for global innovation policy at the Information Technology and Innovation Foundation, told National Review that while many countries around the world are willing to invest heavily in combatting climate change because they see it as an existential global threat, the same zeal falls away when it comes to public health and developing new, life-saving drugs.
Comments